港股异动 大涨近20% 今日起正式进入港股通名单

Core Viewpoint - BaiO Pharmaceutical-B (02315) experienced a significant increase of nearly 20%, closing at 34.3 HKD, following its inclusion in the Hong Kong Stock Connect list effective December 24, 2025 [1] Company Summary - BaiO Pharmaceutical is recognized as a leading preclinical CRO and life sciences company in China, possessing a globally advanced gene editing technology platform [1] - The company has a rich resource of model mice and is actively developing its antibody development business through the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - There is strong growth potential for its overseas business, indicating a promising outlook for future expansion [1]